Cassava Sciences, Inc. (SAVA)
|52 Week Range||2.78-146.06|
|1y Target Est||-|
|Debt / Equity||1.02%||Neutral|
Upgrades & Downgrades
SAVA Stock Fell 23.61%: Details You Should Know
The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know. ...
Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data
As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data appeared first on InvestorPlace. ...
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. ...
The Motley Fool
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease. ...
The Motley Fool
Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential
Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation. ...
Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer's Results
Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have. ...
An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of...
Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment. ...
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14, 2000 and December of that year. On Wednesday, the biopharmaceutical company announ... ...
Cassava Sciences stock price forecast for Q3 after shares rally 27%
Meme stock Cassava Sciences Inc. (NASDAQ:SAVA) shares surged more than 27% on Wednesday after revealing plans to present data on its Alzheimer's drug, Simufilam, on 29th July. Cassava will read out its interim analysis on a 9-month treatment with Sim... ...